Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
New headquarters supports Novocure’s continued growth as it pursues its mission of extending survival in some of the most aggressive forms of cancer
BAAR,
The company opened its first office in
“The opening of our new global headquarters aligns with a significant point in Novocure’s history as we begin our 25th year of business and move closer to realizing the full potential of Tumor Treating Fields therapy,” said Ashley Cordova, Chief Executive Officer, Novocure. “The dynamic life sciences cluster in the
Member of the Government Council of the
Ms. Thalmann-Gut commented, “The Canton of Zug is home to many nationally and internationally successful life sciences and MedTech companies, from large players to innovative start-ups. We are pleased that Novocure has chosen the
ABOUT THE NEW GLOBAL HEADQUARTERS
After many years of being based in Root,
ABOUT TUMOR TREATING FIELDS
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.
To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.
ABOUT NOVOCURE
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.
Novocure’s global headquarters is located in Baar,
FORWARD-LOOKING STATEMENTS
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122842632/en/
INVESTORS:
Ingrid Goldberg: investorinfo@novocure.com
MEDIA:
Catherine Falcetti: media@novocure.com
Source: Novocure